Communiqués presse membre
Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergies
- 17/05/2013 |
- 1:00 pm |
- valerie
ANTONY and BAGNEUX, France, 16 May 2013 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and Stallergenes S.A. (Euronext Paris CAC small), worldwide leader in allergen immunotherapy, announced today that they have entered into a strategic research partnership.
(Français) MAUNA KEA – Présence sans précédent du Cellvizio à la plus grande conférence mondiale sur les maladies digestives (DDW) : plus de 40 présentations scientifiques
- |
- 12:46 pm |
- valerie
(Français) PARIS, le 17 mai 2013 – Mauna Kea Technologies (NYSE Euronext : MKEA, FR0010609263), leader dans le domaine de la biopsie optique, annonce aujourd’hui que 41 présentations sur le Cellvizio® sont au programme scientifique de la Digestive Disease Week (DDW) 2013, démontrant la valeur clinique de la biopsie optique pour des pathologies importantes et très répandues de l’appareil digestif.
CARMAT – Agreement with the Silesian Center for Heart Diseases in Zabrze, Poland, to perform implants of bioprosthetic artificial heart
- |
- 10:14 am |
- valerie
Paris, May 15, 2013 – CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced project of total artificial heart, reports today that the Silesian Center for Heart Diseases in Zabrze, Poland, has agreed to participate into the first clinical implants of CARMAT bioprosthetic artificial heart.
EOS® System Shown to offer Most Accurate Lower Limb Images with Lowest Radiation Dose in New Study
- 16/05/2013 |
- 6:29 pm |
- valerie
Paris, May 16, 2013 – EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced that new research shows the EOS® System offers more accurate lower limb imaging with significantly lower radiation exposure as compared to computed radiography (CR) and CT scan. The study was presented at the Pediatric Orthopaedic Society of North America (POSNA) Annual Meeting in Toronto, Canada, held May 1-4.
CARMAT – Agreement with St Pierre University Hospital, in Brussels, Belgium, to perform implantations of bioprosthetic artificial heart
- |
- 5:15 pm |
- valerie
Paris, May 15, 2013 – CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced project of total artificial heart, reports today that St Pierre University Hospital, in Brussels, Belgium, has agreed to participate into the first clinical implantations of CARMAT’s bioprosthetic artificial heart.
Cellectis Bioresearch-TAL-effector nuclease: Issuance by the USPTO of two new patents.
- |
- 5:10 pm |
- valerie
New Brighton, May 16, 2013 – Cellectis (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US patents (US 8,440,431 and US 8,440,432) directed to TAL-effector nucleases.
CARMAT – Agreement with the University Medical Centre, in Ljubljana, Slovenia, to perform implants of bioprosthetic artificial heart
- 15/05/2013 |
- 10:24 am |
- valerie
Paris, May 15, 2013 – CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced project of total artificial heart, reports today that the University Medical Centre, in Ljubljana, Slovenia, has agreed to participate into the first clinical implants of CARMAT bioprosthetic artificial heart.
CARMAT – Agreement with the Prince Sultan Cardiac Center in Riyadh, Kingdom of Saudi Arabia,to perform implants of bioprosthetic artificial heart
- |
- 10:17 am |
- valerie
Paris, May 15, 2013 – CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced project of total artificial heart, reports today that Prince Sultan Cardiac Center (PSCC) in Riyadh, Kingdom of Saudi Arabia, has agreed to participate into the first clinical implants of CARMAT bioprosthetic artificial heart.
(Français) GENFIT – GFT505 REDUIT LE RISQUE D’ACCIDENTS CARDIOVASCULAIRES par son action sur le ‘REMNANT CHOLESTEROL’
- |
- 9:31 am |
- valerie
(Français) Lille (France), Cambridge (Massachusetts, United States), le 15 mai 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), société biopharmaceutique, engagée dans la découverte et le développement de médicaments, qui intervient sur le diagnostic précoce, la prévention et le traitement des maladies cardiométaboliques et des désordres associés, annonce aujourd’hui que GFT505 réduit une nouvelle composante du risque cardiovasculaire : le cholestérol contenu dans les particules lipidiques autres que les particules LDL et HDL, encore appelé ‘remnant cholesterol’.
VIVALIS – Merger between Intercell and Vivalis planned to complete on May 28, 2013
- 14/05/2013 |
- 10:18 am |
- valerie
Vienna (Austria), Nantes (France) May 14, 2013 – Intercell AG (Intercell, VSE; “ICLL”) and Vivalis SA (Vivalis, NYSE Euronext; “VLS”) today announced that the final administrative step for closing of the proposed merger between the two companies to create Valneva SE (Valneva) has been initiated by filing of the relevant documents with the companies’ register at the Commercial Court of Lyon. This step follows the approval of the proposed merger by the extraordinary general meetings of both companies, the issuance of the pre-merger certificates by the French Commercial Register on April 3, 2013 and by the Austrian Commercial Register on April 12, 2013, and the issuance of the certificate of legality of the merger on April 17, 2013.
